Assess whether the primary endpoint will survive FDA scrutiny (d68472)

SITUATION Regulatory-affairs lead owns this CMC and Development Pathways review in a safety team sitting on a new disproportionate signal. An inspector asking for batch records you cannot produce this week is the triggering event; scientific-advice briefing book is the evidence for whether the primary endpoint will survive FDA scrutiny.

DECISION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. An inspector asking for batch records you cannot produce this week is noise around an already-controlled CMC and Development Pathways process in a safety team sitting on a new disproportionate signal, given scientific-advice briefing book. 2. An inspector asking for batch records you cannot produce this week is the event in scientific-advice briefing book that forces Proceed under protocol for regulatory-affairs lead under Pharma & Life Sciences. 3. Scientific-advice briefing book shows a one-file miss after an inspector asking for batch records you cannot produce this week, not a CMC and Development Pathways program failure. 4. Scientific-advice briefing book cannot decide the primary endpoint will yet after an inspector asking for batch records you cannot produce this week; hold is the only Pharma & Life Sciences close a safety team sitting on a new disproportionate signal can defend.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after an inspector asking for batch records you cannot produce this week. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against an inspector asking for batch records you cannot produce this week and write the one fact that would move the primary endpoint will for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for regulatory-affairs lead in a safety team sitting on a new disproportionate signal.